US 11,746,156 B2
Antibody therapeutics that bind CD123
Heyue Zhou, San Diego, CA (US); and John Dixon Gray, San Diego, CA (US)
Assigned to SORRENTO THERAPEUTICS, INC., San Diego, CA (US)
Filed by Sorrento Therapeutics, Inc., San Diego, CA (US)
Filed on Jan. 15, 2021, as Appl. No. 17/150,884.
Application 17/150,884 is a continuation of application No. 16/135,886, filed on Sep. 19, 2018, granted, now 10,934,361.
Application 16/135,886 is a continuation of application No. 15/093,777, filed on Apr. 8, 2016, granted, now 10,100,118, issued on Oct. 16, 2018.
Claims priority of provisional application 62/144,899, filed on Apr. 8, 2015.
Prior Publication US 2021/0163613 A1, Jun. 3, 2021
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2866 (2013.01) [C07K 2317/21 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
 
1. A fully human anti-CD123 antibody, or an antigen binding fragment thereof, that binds to a CD 123 epitope, said anti-CD123 antibody or antigen-binding fragment thereof comprising:
a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 1 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 2.